Dr. Peter Marks

Recommended reads: PSC, COVID, FDA pledge, sci jobs

Sarthy-et-al-eLife-2020-Fig-2

When you sit down to read science on the weekends lately, assuming you are not primarily a COVID-19 researcher, how much COVID stuff seeps into your reading? As I was going over some of this year’s recommended weekly reads posts here on The Niche, I’ve realized that an increasing amount of COVID-19 research has joined …

Recommended reads: PSC, COVID, FDA pledge, sci jobs Read More »

Politics & FDA clearance of 2 stem cell clinic COVID-19 efforts

Anand-Srivastava

The FDA and its CBER branch have been doing a good job overall in the last 3+ years to tackle the unproven stem cell clinic problem, but lately on the stem cells for COVID-19 front there is reason for real concern. I believe the agency is taking on major risk overall by clearing a vast number of …

Politics & FDA clearance of 2 stem cell clinic COVID-19 efforts Read More »

Striking FDA Hahn & Marks JAMA pub on regenerative clinics

Dr-Stephen-Hahn-Commissioner-of-FDA

It was fascinating to read a new JAMA piece by the FDA on unproven stem cell clinics and other regenerative medicine firms. Many of these guys are profiteering off of buzz about exciting, but mostly unproven technologies. While the JAMA opinion piece reiterates the agency’s commitment to evidence-based regenerative medicine, it also makes some other …

Striking FDA Hahn & Marks JAMA pub on regenerative clinics Read More »

FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms

Roya-Panah-Kosolcharoen

Friday and Saturday showed a burst in FDA activity related to unproven stem cells and regenerative products including a warning letter to the unproven perinatal “stem cell” provider Liveyon. This was an unusual 48-hour period and a very good one for those who believe in science-based regenerative medicine but in my view a bad day …

FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms Read More »

Critical new piece on MD Stem Cells purported Right To Try program: let’s dig into it

Steven-Levy-Jeffrey-Weiss

I’ve been concerned about a stem cell group called MD Stem Cells for many years. Now it comes under more scrutiny from a new must-read piece by Donna Young over at S&P Global. Young’s article reports a puzzling, purported right-to-try (RTT) program that MD Stem Cells appears to working on with Richard Garr. Note that …

Critical new piece on MD Stem Cells purported Right To Try program: let’s dig into it Read More »

Highlights of Science Writers DC Stem Cell Panel with FDA’s Peter Marks

IMG_7988

I’m enjoying attending and speaking at the annual Science Writers 2018 meeting in D.C. where I spoke this morning on a panel about stem cells. The session was specifically on the Wild West of stem cells. You can follow the meeting events on Twitter with the #sciwri18 hashtag. I had three wonderful fellow panelists, Marilynn Marchione of …

Highlights of Science Writers DC Stem Cell Panel with FDA’s Peter Marks Read More »